IN THE SPOTLIGHT

Shaheenah Dawood: EFS with Adjuvant Selpercatinib in Early-Stage RET Fusion–Positive NSCLC

Shaheenah Dawood: EFS with Adjuvant Selpercatinib in Early-Stage RET Fusion–Positive NSCLC

Inferring tumor immune microenvironment -related risk states from pretreatment H&E pathomics and clinical biomarkers to predict checkpoint inhibitor pneumonitis in advanced NSCLC: a multicenter multimodal study

Inferring tumor immune microenvironment -related risk states from pretreatment H&E pathomics and clinical biomarkers to predict checkpoint inhibitor pneumonitis in advanced NSCLC: a multicenter multimodal study

Adjuvant Selpercatinib Looks Promising for Early-Stage RET Fusion-Positive NSCLC

Adjuvant Selpercatinib Looks Promising for Early-Stage RET Fusion-Positive NSCLC

Evaluation of six clinical prognostic scores in NSCLC patients undergoing first line chemoimmunotherapy

Evaluation of six clinical prognostic scores in NSCLC patients undergoing first line chemoimmunotherapy

Lilly’s Retevmo boosts event-free survival in early-stage NSCLC

Lilly’s Retevmo boosts event-free survival in early-stage NSCLC

Cadonilimab (PD-1/CTLA-4 bispecific antibody) combination therapy for driver gene-negative advanced NSCLC: a single-center retrospective real-world study

Cadonilimab (PD-1/CTLA-4 bispecific antibody) combination therapy for driver gene-negative advanced NSCLC: a single-center retrospective real-world study

Stage IIIB ROS1-Positive NSCLC management: crizotinib + surgery + TCM achieves exceptionally prolonged PFS (a case report)

Stage IIIB ROS1-Positive NSCLC management: crizotinib + surgery + TCM achieves exceptionally prolonged PFS (a case report)